Clinical Trials

Houston Metro Urology researchers bring extensive experience and knowledge to our clinical trials and to your treatment. Patient safety is our primary concern. All clinical trials are conducted according to the principals of Good Clinical Practice (GCPs) as mandated by the FDA.

 

Participating in a clinical trial has many potential benefits. These include:

  •  Access to the latest treatments before they are widely available

  • Possible compensation for your time and reimbursement for extra services

  • Closer monitoring of your condition by expert medical professionals

  • Improved medical knowledge that can benefit others

 

Current Enrolling for the following Clinical Trials

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Single Group Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Primary Purpose: Treatment

Official Title: A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

Official Link: click here

Study Type: Observational

Study Design:

  • Observational Model: Case-Only
  • Time Perspective: Prospective

Official Title: Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)

Official Link: click here

Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Official Link: click here

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

Official Link: click here

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Primary Purpose: Treatment

Official Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Official Link: click here

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator)
  • Primary Purpose: Treatment

Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Official Link: click here

Study Type: Observational

Study Design:

  • Observational Model: Cohort
  • Time Perspective: Prospective

Official Title: A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States

Official Link: click here

Study Type: Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

Official Link: click here

Study Type: Interventional

Study Design:

  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Single Group Assignment
  • Masking: Open Label
  • Primary Purpose: Treatment

Official Title: Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Viciniumâ„¢ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG

Official Link: click here

For more information or to enroll in a study please call: 713-634-4405.